Inebilizumab

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 171 publications

Progress in the Treatment of Neuromyelitis Optica Spectrum Disorder: From Pathogenic Insights to Biologics.

Progress in the Treatment of Neuromyelitis Optica Spectrum Disorder: From Pathogenic Insights to Biologics.

Journal: Internal medicine (Tokyo, Japan)

Published: February 23, 2026

A Systematic Review of Erdheim-Chester Disease and IgG4-Related Disease: Building a Diagnostic Framework for the Rheumatologist.

A Systematic Review of Erdheim-Chester Disease and IgG4-Related Disease: Building a Diagnostic Framework for the Rheumatologist.

Journal: Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases

Published: February 23, 2026

Inebilizumab, a novel anti-CD19 antibody for treatment of IgG4-related disease: an overview from clinical trials.

Inebilizumab, a novel anti-CD19 antibody for treatment of IgG4-related disease: an overview from clinical trials.

Journal: Expert opinion on biological therapy

Published: February 20, 2026

The evolution and current status of anti-B-cell therapies in autoimmune neurologic diseases.

The evolution and current status of anti-B-cell therapies in autoimmune neurologic diseases.

Journal: Handbook of clinical neurology

Published: January 12, 2026

Real-World Efficacy and Safety of Neuromyelitis Optica Spectrum Disorder Disease-Modifying Treatments.

Real-World Efficacy and Safety of Neuromyelitis Optica Spectrum Disorder Disease-Modifying Treatments.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: January 06, 2026

Inebilizumab treatment in Japanese patients with IgG4-related disease: a subgroup analysis of a randomized, double-blind, placebo-controlled, phase 3 trial (MITIGATE).

Inebilizumab treatment in Japanese patients with IgG4-related disease: a subgroup analysis of a randomized, double-blind, placebo-controlled, phase 3 trial (MITIGATE).

Journal: Modern rheumatology

Published: December 24, 2025

Systematic Review and Model-Based Meta-Analysis of Targeted Drugs for Systemic Sclerosis.

Systematic Review and Model-Based Meta-Analysis of Targeted Drugs for Systemic Sclerosis.

Journal: Pharmaceutics

Published: December 13, 2025

A recalcitrant case of pemphigus treated with inebilizumab.

A recalcitrant case of pemphigus treated with inebilizumab.

Journal: JAAD case reports

Published: December 09, 2025

What is in the Neuromuscular Junction Literature?

What is in the Neuromuscular Junction Literature?

Journal: Journal of clinical neuromuscular disease

Published: December 03, 2025

Integrating B Cell Differentiation Model With Real-World Data Informs Determinants for Antibody-Secreting Cell Depletions in Systemic Sclerosis.

Integrating B Cell Differentiation Model With Real-World Data Informs Determinants for Antibody-Secreting Cell Depletions in Systemic Sclerosis.

Journal: CPT: pharmacometrics & systems pharmacology

Published: November 26, 2025

Evaluating inebilizumab in the treatment of generalized myasthenia gravis.

Evaluating inebilizumab in the treatment of generalized myasthenia gravis.

Journal: Immunotherapy

Published: November 25, 2025

IgG4-related sclerosing cholangitis: navigating diagnostic dilemmas and the challenge of relapse.

IgG4-related sclerosing cholangitis: navigating diagnostic dilemmas and the challenge of relapse.

Journal: Frontiers in medicine

Published: October 26, 2025

Showing 1-12 of 171

Last Updated: 04/28/2026